Lung Cancer

The discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) ends as each expert discusses their final thoughts.

Panelists conclude their discussion by commenting on areas of unmet need and sharing personal perspectives on factors that may change clinical practice for SCLC in the future.

Key opinion leaders in lung cancer share personal thoughts on the potential for bispecific agents and the overall impact of inhibiting molecular targets.

Oncology experts provide insight on screening methods available and discuss strategies that may address challenges in identification of targetable mutations/tumor profiles in non–small cell lung cancer (NSCLC).

Jonathan W. Goldman, MD, discusses key takeaways from the phase 3 CASPIAN trial in patients with extensive-stage small cell lung cancer.

Martin Dietrich, MD, PhD, shares how he navigates the non–small cell lung cancer (NSCLC) treatment landscape.

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.

The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Chad V. Pecot, MD, discusses addressing mechanisms of resistance with new targeted therapies in non–small cell lung cancer.

James Stevenson, MD, discusses ongoing research efforts that are generating excitement in extensive-stage small cell lung cancer.

Computed tomography-based image guidance during radiation therapy could be a method of identifying patients who require a complete workup for COVID-19.

Jonathan Spicer, MD, PhD, discusses the efficacy observed with neoadjuvant nivolumab plus platinum-doublet chemotherapy in patients with resectable non–small cell lung cancer.

The addition of toripalimab to chemotherapy resulted in a significant improvement in progression-free survival compared with chemotherapy alone when given as first-line treatment in patients with non–small cell lung cancer, meeting the primary end point of the phase 3 CHOICE-01 trial.

Nivolumab followed by treatment with tumor-infiltrating lymphocytes was generally safe and found to have clinical benefit in patients with metastatic non–small cell lung cancer.

An overview of TKIs in ROS1-rearranged non–small cell lung cancer (NSCLC) and updated trial results that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting.

Recommendations for EGFR testing in patients with non–small cell lung cancer based on the wide heterogeneity of these mutations.

Mark A. Socinski, MD, highlights the targeted agents available to treat non–small cell lung cancer with EGFR mutations.

Anne Chiang, MD, PhD, reviews the study design of 2 clinical trials, adding a third agent to the standard-of-care regimen of chemotherapy plus I/O; Stephen Liu, MD, discusses clinical trials in limited-stage disease.

Thoracic oncology expert Vivek Subbiah, MD, provides an overview of recent clinical trials studying agents targeting DNA damage for the treatment of small cell lung cancer.

Experts have a discussion about their preferred treatment approach for newly diagnosed ALK-rearranged non–small cell lung cancer (NSCLC).

Recommendations for mitigating and managing common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors.

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

Jonathan W. Goldman, MD, discusses the significance of the phase 3 CASPIAN and IMpower133 trials in small cell lung cancer and efforts made to optimize molecular testing.

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the rationale to target TROP-2 in lung cancer.

Erin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.

Edgardo S. Santos, MD, discusses the potential role for CEACAM5- and KEAP1-targeted therapies in non–small cell lung cancer.

Dr. Chachoua discusses key guidelines for lung cancer screening, the psychological and financial implications of screening, and the opportunities of a screening initiative instated by NYU Langone Health.

A summary of recent data that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for ALK-rearranged non–small cell lung cancer (NSCLC).